Among the sampling hospitals in China, insulin glargine – a long-acting insulin analogue – held a share of 35 percent in human insulin and insulin analogues market in 2018. Insulin therapy is mainly used to treat type 1 diabetes in which pancreas no longer produce enough or any insulin to lower blood sugar level. The market size of human insulin and insulin analogs in China was projected to expand with a compound annual growth rate of 4.4 percent until 2030.
…. more: Statista.com (Quelle/Source)